Abstract
Background: Bombax ceiba (B. ceiba) L. is an important plant in the Malvaceae family, widely distributed across tropical and subtropical areas of Africa, Asia and Australia. The medicinal properties of the plant are highly valued under various forms of traditional medicines such as Ayurveda, Siddha, Unani, and others. It has been used to treat gastrointestinal, skin, urinary, and wound-healing ailments for a long time. The experimental literature is increasingly becoming popular, but a focused integration linking pharmacognostic identity to mechanistic pharmacology is largely missing. Aim: The objective of the mini-review is to combine classical pharmacognosy with molecular pharmacology of B. ceiba. As a future orientation in drug development, the morphological authentication, phytochemical characterisation and diversity and the experimentally deciphered bioactivities together with the impact of innovative nano-formulation may be brought into a unified document defined in a “bench-to-biological-pathway”. Methods: The pharmacognostic characterisation, herbal medicine and ethnopharmacology, phytochemistry, and pharmacology of species belonging to the genus Bombax, specifically B. ceiba, were systematically reviewed. This allowed us to assess its medical utility and market potential in the context of a rapidly evolving functional food industry. Relevant information was included in an operational model of pharmacognosy phytochemistry mechanism. Result: Stigmasterol, β-amyrin palmitate, lupeol palmitate, and malvalic acid are compounds purified from the parts of B. ceiba. The plant is abundantly loaded with lupeol, mangiferin, β-sitosterol, quercetin and its derivatives, shamimin, anthocyanins, naphthoquinones, and others and also possesses a vast scope of applications in cosmetics, pharmacy, and food industry. Conclusion: B. ceiba emerges as a good multi-target ethnomedicine; it has pharmacognostic identity and good pharmacological preclinical evidence. According to findings, there is a correlation between conventional uses and modulation of the NF-κB, Nrf2, MAPK, and AMPK pathways Consequently, it seems likely a good candidate for phytopharmaceutical preparation. In future perspective, it is important to establish protocols for extracting the plant, study pharmacokinetic, and implement controlled clinical trials to transform this wealth into evidence-based and easily perceptible therapeutic agents. Major Findings: B. ceiba L. covers key bioactives — lupeol, mangiferin, β-sitosterol, and quercetin derivatives — that modulate NF-κB, Nrf2, MAPK, and AMPK pathways, granting anti-inflammatory, antioxidant, hepatoprotective, and antidiabetic activities, though the absence of controlled clinical trials and standardised extracts remains a critical translational gap demanding systematic pharmacokinetic and clinical validation.

This publication has 83 references indexed in Scilit: